Assessment of factors affecting the mental condition of patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

被引:2
|
作者
Gibek, Katarzyna [1 ]
Sacha, Tomasz [2 ]
机构
[1] Jagiellonian Univ Med Coll, Sw Anny St 12,Room 7a, Krakow, Poland
[2] Jagiellonian Univ Med Coll, Chair & Dept Hematol, Krakow, Poland
关键词
cancer; leukemia; psychiatric disorders; QUALITY-OF-LIFE; PSYCHIATRIC MORBIDITY; CANCER; DEPRESSION; ANXIETY; ADJUSTMENT; SYMPTOMS; DISTRESS; PREDICTORS; DISORDERS;
D O I
10.12740/PP/OnlineFirst/130264
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Aim. The aim of the study was to make a general assessment of mental health, including signs of somatization, depression, anxiety, and functional disorders, in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) and to assess the impact of factors such as the duration of the disease, side effects of therapy, age, and gender on the occurrence of the above-mentioned disorders. Another goal was to identify patients at risk of developing mental disorders. Method. The study involved 91 patients and was conducted at the Hematology Clinic of the University Hospital in Krakow. The following questionnaires were used to assess mental health: survey created by the author, David Goldberg's questionnaire GHQ-28, and the four-dimensional 4DSQ, measuring four dimensions of the mental condition. Results. The average level of the mental condition of the studied group was demonstrated. 29 people with mental disorders were identified. Women and people living alone obtained worse results in almost all dimensions of the questionnaires. The analysis revealed that factors such as age, number of side effects and gender significantly affect mental disorders in the studied group. A significant and positive correlation has been found between the number of side effects and the presence of somatization signs. Mediocre correlations occurred between age and mental disorders and all dimensions of the GHQ-28. Conclusions. The obtained results indicate that attempts should be made to reduce side effects among CML patients. Visiting the psychologist to work on the acceptance of the disease, psychoeducation, behavioral therapy, and contact with a psychiatrist to consider the introduction of pharmacotherapy is recommended. All of these methods may improve a patient's quality of life.
引用
收藏
页数:15
相关论文
共 50 条
  • [41] Cardiovascular Events Among Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)
    Sam, Princy Yohannan
    Ahaneku, Hycienth
    Nogueras-Gonzalez, Graciela M.
    Jabbour, Elias
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    Daver, Naval
    Kadia, Tapan
    Burger, Jan
    Pierce, Sherry
    DiNardo, Courtney D.
    Ravandi, Farhad
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [42] Influence of complex variant chromosomal translocations in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
    Stagno, Fabio
    Vigneri, Paolo
    Del Fabro, Vittorio
    Stella, Stefania
    Cupri, Alessandra
    Massimino, Michele
    Consoli, Carla
    Tambe, Loredana
    Consoli, Maria Letizia
    Antolino, Agostino
    Di Raimondo, Francesco
    ACTA ONCOLOGICA, 2010, 49 (04) : 506 - 508
  • [43] Costs related to adverse events in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors in Canada
    Newton, N.
    Goetghebeur, M. M.
    Ouagari, K. E.
    VALUE IN HEALTH, 2008, 11 (03) : A62 - A63
  • [44] Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors
    Atteya, Asmaa
    Ahmad, Aiman
    Daghstani, Dima
    Mushtaq, Kamran
    Yassin, Mohamed A.
    CANCER CONTROL, 2020, 27 (01)
  • [45] Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Phillips, Kristin M.
    Pinilla-Ibarz, Javier
    Sotomayor, Eduardo
    Lee, Morgan R.
    Jim, Heather S. L.
    Small, Brent J.
    Sokol, Lubomir
    Lancet, Jeffrey
    Tinsley, Sara
    Sweet, Kendra
    Komrokji, Rami
    Jacobsen, Paul B.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (04) : 1097 - 1103
  • [46] Evaluation of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors
    Atteya, Asmaa
    Ahmad, Aiman
    Daghstani, Dima
    Yassin, Mohamed A.
    BLOOD, 2019, 134
  • [47] PREGNANCIES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYSOSINE KINASE INHIBITORS
    Wang, A.
    Zhou, L.
    HAEMATOLOGICA, 2013, 98 : 555 - 555
  • [48] Atherosclerosis Risk Factors in Chronic Myeloid Leukemia Patients Under Durable Tyrosine Kinase Inhibitors Therapy
    Shnalieva, Nadezhda
    Osipov, Iurii
    Zammoeva, Darina
    Kabanov, Pavel
    Rotar, Oxana
    Boyarinova, Maria
    Dyshluk, Marina
    Salogub, Galina
    Vasilieva, Elena
    Lomaia, Elza
    BLOOD, 2024, 144 : 6617 - 6618
  • [49] When Can Tyrosine Kinase Inhibitors Be Discontinued in Patients With Chronic Myeloid Leukemia?
    Mahon, Francois-Xavier
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (02) : 101 - 103
  • [50] Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors
    Kondapalli, Lavanya
    Worth, Sarah
    Hawi, Riem
    Vachhani, Pankit
    Arora, Garima
    Bhatia, Ravi
    Lenneman, Carrie G.
    VASCULAR MEDICINE, 2020, 25 (03) : 246 - 254